Modulating Immune Responses and Inflammation

ABSTRACT

New disease-modifying therapeutic options for immune diseases in general and immune-related cardiovascular diseases are urgently needed. Various innovative therapies are currently developed ranging from small molecules and natural compounds to biopharmaceuticals. This article summarizes the overview of possible points of intervention for an ongoing immune response and lists examples of currently developed therapeutic exploitations of these targets. Research and development for the treatment of autoimmune and inflammatory diseases in general will most likely be fruitful also for therapy of immune-related cardiovascular diseases such as myocarditis and atherosclerosis and should be closely followed by research groups focused on cardiovascular immunology.

KEYWORDS

Inflammation - immune response - immune modulation - myocarditis

REFERENCES

• 1 Ley K, Laudanna C, Cybulsky M I, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated.  Nat Rev Immunol. 2007;  7(9) 678-689
• 2 Eming S A, Krieg T, Davidson J M. Inflammation in wound repair: molecular and cellular mechanisms.  J Invest Dermatol. 2007;  127(3) 514-525
• 3 Branton M H, Kopp J B. TGF-beta and fibrosis.  Microbes Infect. 1999;  1(15) 1349-1365
• 4 Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases.  Cell Biochem Biophys. 2009;  55(2) 55-79
• 5 Aktas O, Kieseier B, Hartung H P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.  Trends Neurosci. 2010;  , January 4 (Epub ahead of print)
• 6 Schett G. Bone formation versus bone resorption in ankylosing spondylitis.  Adv Exp Med Biol. 2009;  649 114-121
• 7 Libby P. Inflammation in atherosclerosis.  Nature. 2002;  420(6917) 868-874
• 8 Kühl U, Schultheiss H P. Viral myocarditis: diagnosis, aetiology and management.  Drugs. 2009;  69(10) 1287-1302
• 9 Hill S L, Rose N R. The transition from viral to autoimmune myocarditis.  Autoimmunity. 2001;  34(3) 169-176
• 10 Feldman A M, McNamara D. Myocarditis.  N Engl J Med. 2000;  343(19) 1388-1398
• 11 Santangeli P, Pieroni M. Immunosuppressive and antiviral treatment of inflammatory cardiomyopathy.  Recent Pat Cardiovasc Drug Discov. 2009;  4 88-97
• 12 Reiser H, Stadecker M J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases.  N Engl J Med. 1996;  335(18) 1369-1377
• 13 Linsley P S, Ledbetter J A. The role of the CD28 receptor during T cell responses to antigen.  Annu Rev Immunol. 1993;  11 191-212
• 14 Krummel M F, Allison J P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.  J Exp Med. 1995;  182(2) 459-465
• 15 Moreland L, Bate G, Kirkpatrick P. Abatacept.  Nat Rev Drug Discov. 2006;  5(3) 185-186
• 16 Matloubian M, Lo C G, Cinamon G et al.. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.  Nature. 2004;  427(6972) 355-360
• 17 Menge T, Weber M S, Hemmer B et al.. Disease-modifying agents for multiple sclerosis: recent advances and future prospects.  Drugs. 2008;  68(17) 2445-2468
• 18 Gräler M H, Goetzl E J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.  FASEB J. 2004;  18(3) 551-553
• 19 Meyer L M, Miller F R, Rowen M J, Bock G, Rutzky J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid).  Acta Haematol. 1950;  4(3) 157-167
• 20 Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.  Nat Rev Drug Discov. 2005;  4(6) 510-518
• 21 Bain B, Brazil M. Adalimumab.  Nat Rev Drug Discov. 2003;  2(9) 693-694
• 22 Garrison L, McDonnell N D. Etanercept: therapeutic use in patients with rheumatoid arthritis.  Ann Rheum Dis. 1999;  58(suppl 1) I65-I69
• 23 Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab.  Handb Exp Pharmacol. 2008;  (181) 151-160
• 24 Fabian M A, Biggs III W H, Treiber D K et al.. A small molecule-kinase interaction map for clinical kinase inhibitors.  Nat Biotechnol. 2005;  23(3) 329-336
• 25 Druker B J. Perspectives on the development of a molecularly targeted agent.  Cancer Cell. 2002;  1(1) 31-36
• 26 Deininger M W, Druker B J. Specific targeted therapy of chronic myelogenous leukemia with imatinib.  Pharmacol Rev. 2003;  55(3) 401-423
• 27 Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion.  Exp Hematol. 2007;  35(8) 1266-1271
• 28 Koretzky G A, Abtahian F, Silverman M A. SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond.  Nat Rev Immunol. 2006;  6(1) 67-78